• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不明原因出血性疾病患者的纤溶酶原生成分析。

Plasmin generation analysis in patients with bleeding disorder of unknown cause.

机构信息

Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Department of Pathology and Laboratory Medicine, UNC Blood Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC.

出版信息

Blood Adv. 2024 Nov 12;8(21):5663-5673. doi: 10.1182/bloodadvances.2024012855.

DOI:10.1182/bloodadvances.2024012855
PMID:39231312
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11564053/
Abstract

Bleeding disorder of unknown cause (BDUC) is a diagnosis of exclusion after evaluation of plasma coagulation and platelet function. Patients with BDUC (n = 375) recorded in the Vienna Bleeding Biobank were analyzed in comparison with healthy controls (HCs; n = 100) in this case-control study. Plasmin generation (PG) parameters were analyzed using calibrated fluorescence detection in citrated plasma. Turbidimetric plasma clot formation/lysis of 293 (78%) patients with BDUC and confocal microscopy of clots from representative patients with BDUC (n = 6) and HCs (n = 9) were assessed. In the PG analysis, patients with BDUC exhibited lower velocity and peak plasmin levels but a higher endogenous plasmin potential than HCs. Peak plasmin levels correlated with maximum clot absorbance but not with clot lysis time. Clot absorbance is an indicator of clot fiber density. Confocal microscopy analysis revealed a tendency towards thicker fibers in clots of patients with BDUC, which negatively correlated with peak plasmin (r = -0.561; P = .030). Peak plasmin correlated weakly with factor XIII, but not with other fibrinolytic factors (alpha2-antiplasmin, thrombin activatable fibrinolysis inhibitor, or plasminogen activator inhibitor 1) or bleeding severity. A model comprising fibrinogen and parameters of PG yielded high predictive power in discriminating between patients with BDUC and HCs across a fivefold stratified cross validation (80% of data; mean area under the curve [AUC], 0.847). The model generalized well to unseen data (20% of data; AUC, 0.856). Overall, patients with BDUC counterintuitively exhibited reduced peak plasmin levels, potentially related to altered clot structure.

摘要

原因不明的出血性疾病 (BDUC) 是在评估血浆凝血和血小板功能后排除其他原因的诊断。在这项病例对照研究中,对维也纳出血生物库中记录的 375 例 BDUC 患者(n=375)与 100 例健康对照者(HCs;n=100)进行了分析。使用柠檬酸血浆中的校准荧光检测分析纤溶酶生成 (PG) 参数。评估了 293 例(78%)BDUC 患者的浊度血浆凝块形成/溶解和 6 例 BDUC 患者和 9 例 HCs 患者的代表性凝块的共聚焦显微镜。在 PG 分析中,BDUC 患者的速度和峰值纤溶酶水平较低,但内源性纤溶酶潜能较高。峰值纤溶酶水平与最大凝块吸光度相关,但与凝块溶解时间无关。凝块吸光度是凝块纤维密度的指标。共聚焦显微镜分析显示,BDUC 患者的凝块纤维较厚,呈负相关,与峰值纤溶酶呈负相关(r=-0.561;P=0.030)。峰值纤溶酶与因子 XIII 弱相关,但与其他纤维蛋白溶解因子(α2-抗纤溶酶、凝血酶激活的纤溶抑制物或纤溶酶原激活物抑制剂 1)或出血严重程度无关。包含纤维蛋白原和 PG 参数的模型在五倍分层交叉验证中具有较高的预测能力,可区分 BDUC 患者和 HCs(80%的数据;平均曲线下面积 [AUC],0.847)。该模型在未见数据(20%的数据;AUC,0.856)中概括良好。总体而言,BDUC 患者的峰值纤溶酶水平出人意料地降低,可能与改变的凝块结构有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0494/11564053/bdb4922e1205/BLOODA_ADV-2024-012855-gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0494/11564053/d7408913da0e/BLOODA_ADV-2024-012855-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0494/11564053/19fb673ef40e/BLOODA_ADV-2024-012855-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0494/11564053/283a9ec490ec/BLOODA_ADV-2024-012855-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0494/11564053/e4d0762bf391/BLOODA_ADV-2024-012855-gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0494/11564053/1e55f371a913/BLOODA_ADV-2024-012855-gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0494/11564053/0b1f6d0c4535/BLOODA_ADV-2024-012855-gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0494/11564053/bdb4922e1205/BLOODA_ADV-2024-012855-gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0494/11564053/d7408913da0e/BLOODA_ADV-2024-012855-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0494/11564053/19fb673ef40e/BLOODA_ADV-2024-012855-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0494/11564053/283a9ec490ec/BLOODA_ADV-2024-012855-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0494/11564053/e4d0762bf391/BLOODA_ADV-2024-012855-gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0494/11564053/1e55f371a913/BLOODA_ADV-2024-012855-gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0494/11564053/0b1f6d0c4535/BLOODA_ADV-2024-012855-gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0494/11564053/bdb4922e1205/BLOODA_ADV-2024-012855-gr6.jpg

相似文献

1
Plasmin generation analysis in patients with bleeding disorder of unknown cause.不明原因出血性疾病患者的纤溶酶原生成分析。
Blood Adv. 2024 Nov 12;8(21):5663-5673. doi: 10.1182/bloodadvances.2024012855.
2
Accelerated Fibrinolysis: A Tendency to Bleed?加速纤维蛋白溶解:出血倾向?
Hamostaseologie. 2025 Aug;45(4):312-319. doi: 10.1055/a-2561-6786. Epub 2025 Apr 27.
3
Fibrinolysis is impaired in patients with primary immune thrombocytopenia.纤维蛋白溶解在原发性免疫性血小板减少症患者中受损。
J Thromb Haemost. 2024 Nov;22(11):3209-3220. doi: 10.1016/j.jtha.2024.07.034. Epub 2024 Aug 28.
4
Thrombin-generating potential, plasma clot formation, and clot lysis are impaired in patients with bleeding of unknown cause.在不明原因出血的患者中,凝血酶生成能力、血浆血栓形成和血栓溶解受到损害。
J Thromb Haemost. 2019 Sep;17(9):1478-1488. doi: 10.1111/jth.14529. Epub 2019 Jul 15.
5
Utility of Global Hemostatic Assays in Patients with Bleeding Disorders of Unknown Cause.全球止血检测在不明原因出血性疾病患者中的应用。
Hamostaseologie. 2024 Oct;44(5):358-367. doi: 10.1055/a-2330-9112. Epub 2024 Jul 1.
6
A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.直接口服抗凝药依度沙班通过增强人血浆中的纤溶酶生成加速纤维蛋白溶解:依赖于凝血酶激活的纤溶抑制物。
J Thromb Thrombolysis. 2019 Jul;48(1):103-110. doi: 10.1007/s11239-019-01851-8.
7
Application of a plasmin generation assay to define pharmacodynamic effects of tranexamic acid in women undergoing cesarean delivery.应用纤溶酶生成试验来确定氨甲环酸对剖宫产女性的药效学作用。
J Thromb Haemost. 2021 Jan;19(1):221-232. doi: 10.1111/jth.15114. Epub 2020 Dec 26.
8
Laboratory evaluation of patients with undiagnosed bleeding disorders.未确诊出血性疾病患者的实验室评估。
Blood Coagul Fibrinolysis. 2016 Jul;27(5):500-5. doi: 10.1097/MBC.0000000000000444.
9
Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis.无细胞游离 DNA 调节脓毒症中的血栓结构并损害纤维蛋白溶解。
Arterioscler Thromb Vasc Biol. 2015 Dec;35(12):2544-53. doi: 10.1161/ATVBAHA.115.306035. Epub 2015 Oct 22.
10
No increased systemic fibrinolysis in women with heavy menstrual bleeding.月经过多女性无全身性纤维蛋白溶解增加。
J Thromb Haemost. 2014 Sep;12(9):1488-93. doi: 10.1111/jth.12645. Epub 2014 Jul 23.

引用本文的文献

1
Targeting hemostatic enzymes: from mechanistic insights to therapeutic frontiers.靶向止血酶:从机制洞察到治疗前沿
Curr Opin Hematol. 2025 Jul 15. doi: 10.1097/MOH.0000000000000884.
2
Altered clot structure in pregnant women who will develop postpartum hemorrhage.将发生产后出血的孕妇的凝血结构改变。
Res Pract Thromb Haemost. 2025 Jan 16;9(1):102683. doi: 10.1016/j.rpth.2025.102683. eCollection 2025 Jan.

本文引用的文献

1
Predelivery Haemostatic Biomarkers in Women with Non-Severe Postpartum Haemorrhage.非严重产后出血女性产前止血生物标志物
J Clin Med. 2024 Jul 19;13(14):4231. doi: 10.3390/jcm13144231.
2
Standardization of definition and management for bleeding disorder of unknown cause: communication from the SSC of the ISTH.不明原因出血性疾病定义和管理的标准化:ISTH SSC 的交流。
J Thromb Haemost. 2024 Jul;22(7):2059-2070. doi: 10.1016/j.jtha.2024.03.005. Epub 2024 Mar 20.
3
Fibrinolysis: an illustrated review.纤维蛋白溶解:图文并茂的综述。
Res Pract Thromb Haemost. 2023 Feb 17;7(2):100081. doi: 10.1016/j.rpth.2023.100081. eCollection 2023 Feb.
4
Risk factors for future bleeding in patients with mild bleeding disorders: longitudinal data from the Vienna Bleeding Biobank.轻度出血性疾病患者未来出血的风险因素:来自维也纳出血生物库的纵向数据。
J Thromb Haemost. 2023 Jul;21(7):1757-1768. doi: 10.1016/j.jtha.2023.03.006. Epub 2023 Mar 15.
5
Fibrinogen and Factor XIII in Venous Thrombosis and Thrombus Stability.纤维蛋白原和因子 XIII 在静脉血栓形成和血栓稳定性中的作用。
Arterioscler Thromb Vasc Biol. 2022 Aug;42(8):931-941. doi: 10.1161/ATVBAHA.122.317164. Epub 2022 Jun 2.
6
Fibrinolytic assays in bleeding of unknown cause: Improvement in diagnostic yield.不明原因出血的纤溶活性检测:诊断率的提高
Res Pract Thromb Haemost. 2022 Mar 15;6(2):e12681. doi: 10.1002/rth2.12681. eCollection 2022 Feb.
7
Thrombin generation measured by two platforms in patients with a bleeding tendency: Comment.通过两种平台对有出血倾向患者的凝血酶生成进行测量:评论
J Thromb Haemost. 2021 Nov;19(11):2896-2899. doi: 10.1111/jth.15524.
8
Thrombomodulin in patients with mild to moderate bleeding tendency.伴有轻度至中度出血倾向患者的血栓调节蛋白。
Haemophilia. 2021 Nov;27(6):1028-1036. doi: 10.1111/hae.14433. Epub 2021 Oct 10.
9
How I treat bleeding disorder of unknown cause.我如何治疗原因不明的出血性疾病。
Blood. 2021 Nov 11;138(19):1795-1804. doi: 10.1182/blood.2020010038.
10
Natural anticoagulants: A missing link in mild to moderate bleeding tendencies.天然抗凝剂:轻度至中度出血倾向的缺失环节。
Haemophilia. 2021 Sep;27(5):701-709. doi: 10.1111/hae.14356. Epub 2021 Jun 10.